Drug intelligence / Profile preview

B4t2-100

Development stage: Preclinical
Lead developer: Bio4t2
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

B4t2-100 is an autologous, bispecific chimeric antigen receptor T-cell (CAR-T) therapy being developed by Bio4t2 for the treatment of solid cancers. The therapy is engineered to recognize two distinct, undisclosed cell surface antigens simultaneously. This dual-targeting approach is designed to enhance tumor recognition and killing while potentially overcoming tumor heterogeneity and antigen escape, which are significant barriers in treating solid tumors with CAR-T therapies. As of early 2024, B4t2-100 is in the preclinical and pilot trial stages of development.

Beyond the preview

Go deeper on B4t2-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B4t2-100.

Explore the full profile